INFeD® improved the hemoglobin response to erythropoietic therapy in patients with documented INFeD® full Prescribing Information. Watson Pharma, Inc. 1 mL of INFeD provides 50 mg of elemental iron UpToDate (courtesy of Lexicomp), or the prescribing information. INFeD: INFeD is administered by intramuscular or intravenous injection. Before . during the acute phase of infectious renal disease (manufacturer’s information) . Therefore, the therapeutic prescription use of iron is usually compatible with.

Author: JoJozilkree Kazibar
Country: Tajikistan
Language: English (Spanish)
Genre: Software
Published (Last): 25 July 2011
Pages: 163
PDF File Size: 19.63 Mb
ePub File Size: 18.61 Mb
ISBN: 763-6-94749-808-3
Downloads: 7926
Price: Free* [*Free Regsitration Required]
Uploader: Goltilrajas

Use actual prewcribing weight if less than lean body weight. It would be illogical for a patient to receive both iron supplementation and deferoxamine simultaneously.

U.S. Prescribing Information Disclaimer

Iron dextran is administered intramuscularly or intravenously. Serious anaphylactoid reactions require appropriate resuscitative measures.

While iron is excreted into breast-milk, the iron content of breast milk is not readily affected by the iron content of the maternal diet or the maternal serum iron level.

Do not add therapeutic doses of iron dextran to total parenteral nutrition TPN solutions; iron dextran may destabilize the mixture or cause the cracking of the TPN emulsion. In general, do not administer parenteral iron concomitantly with other iron preparations e.

Iron dextran (INFeD) | – A Hematology Oncology Wiki

Parenteral iron dextran therapy is associated with a risk of serious hypersensitivity reactions or anaphylaxis. Patients with a significant history of allergies e. Distribution of iron dextran following intramuscular or intravenous injection involves uptake by reticuloendothelial cells of the liver, spleen, and bone marrow.

If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA. Inadequate iron stores will interfere with the therapeutic response to these agents e.


There are limits to the volume of iron dextran that may be injected IM per 24 hours based on patient infor,ation and weight; see dosage guidelines. Give DexFerrum test doses gradually over at least 5 minutes. Ferric iron is then gradually released into the plasma where it combines rapidly with transferrin.

Cardiac disease, hypotension, intravenous administration.

To avoid staining of subcutaneous tissue, use the Z-track technique of injection. Parenteral administration of iron dextran may exacerbate joint pain and swelling in patients with rheumatoid arthritis, ankylosing spondylitis, or systemic lupus erythematosus SLE. These dimercaprol-iron complexes are more toxic than the metal alone, especially to the kidneys.

Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed. If test dose uneventful, give the remainder of the total dose as 50 mg of elemental iron per day IM or slow IV until the total calculated dose is given.

Cardiovascular adverse effects may also occur with iron dextran therapy, and do not necessarily indicate hypersensitivity. A value of If test dose uneventful, give the remainder of the total dose as 25 mg of iron dextran per day IM or slow IV until the total calculated dose see equation is given. Concurrent use of deferiprone with iron supplements has not been studied.

Ferritin and transferrin are also recommended monitoring parameters. The factors that affect the risk for anaphylactic-type reactions to iron dextran products are not fully known but limited clinical data suggest the risk may be increased among patients with a history of drug allergy or multiple drug allergies.

DO NOT mix iron dextran with other medications. Supplemental iron may be needed during maintenance therapy to facilitate erythropoiesis. Recipient’s Email Separate multiple email address with a comma Please enter valid email address Recipient’s email is required.

  AR 623-105 PDF

The first stage involves an inflammatory reaction at the site of injection which aids the passage of the drug into the lymphatic system. Since deferiprone has the potential to bind polyvalent cations e. Before administering therapeutic doses, a test dose of 25 mg 0.

In the second stage, macrophages ingest the iron dextran and enter the lymphatic system and eventually the blood. Iron dextran is contraindicated for use in patients with anemia not infde with iron deficiency.

Iron dextran injection contains 50 mg of elemental iron per mL. Some patients with chronic hepatic disease may also have hemochromatosis or moderate iron overload in hepatic tissues.

Infants and Children 4 months and older weighing 5 to 9.

Iron dextran (INFeD)

Administer supplemental iron therapy when serum ferritin is Fosinopril: Minor Inadequate iron invormation will interfere with the therapeutic response to epoetin alfa e. Total Dose Intravenous Infusion []: The extent of risk for anaphylactoid reactions to any specific iron dextran product is unknown and may vary among products.

Informatioj deeply into the upper outer quadrant of the buttock gluteus maximus only using a 2- or 3-inch, or gauge needle. Observe patient for at least 1 hour after test dose administration. Unnecessary or prolonged administration of iron may lead to iron overload and consequently the possibility of exogenous hemosiderosis.